Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs And More
Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items concerning the last few days of January and the first two weeks of February 2024.
See previous edition: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm Reduction Hub And More
Research
Comparative Review On Efficacy, Safety, Pharmacokinetics and Binding Profile of Serotonergic Psychedelics by MindMed’s (NASDAQ:MNMD) Swiss research collaborators (read.)
Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions (read.)
Indigenous psilocybin mushroom practices: An annotated bibliography (read.)
Tune In, & Get Smart
Feb. 14 online event “Exploring MDMA on Valentine’s Day: Unveiling the Science Behind the ‘Love Drug’” led by Tactogen’s CEO Matt Baggott (register.)
Feb. 15 event in NYC: “Inside the Emerging Psychedelic Underground in China” (learn more.)
Evgeny Lebedev, owner of Independent & Evening Standard newspaper, shared his first ayahuasca experience with Prof. David Nutt (listen.)
The Standard interviewed “the family leading the psychedelic revolution,” Amanda Feilding and Cosmo Feilding-Mellen (read.)
“When will psychedelics be legal?,” a NatGeo review (read.)
“FDA Scientist Warns Psychedelic Trials Suffer a ‘Nocebo Effect’,” by Bloomberg (read.)
“Unwanted personality changes after psychedelics,” by Jules Evans (read.)
“Eight Frequently Asked Questions About Ayahuasca Globalization,” written by …